---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-22-000082"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:43:17.029007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer opts into LianBio's RSV drug sisunatovir rights in China & Singapore; $20M upfront, up to $135M milestones

## Summary
- $20M upfront payment from previously restricted cash paid by Pfizer in 2020 under the existing strategic collaboration.
- Up to $135M in potential development and commercial milestone payments plus tiered low single-digit percent of net sales.
- Pfizer assumes all development/commercial costs in the region and releases LianBio from its royalty and milestone obligations to ReViral.
- LianBio expects the transaction to extend cash runway through end of 2024.

## SEC filing metadata
- accession: 0001831283-22-000082
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/0001831283-22-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/lian-20221216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-22-000082
- JSON: https://secwatch.observer/filing/0001831283-22-000082.json
- Plain text: https://secwatch.observer/filing/0001831283-22-000082.txt

## Key facts
- Material Agreements
  LianBio entered into Commercial Agreement with Pfizer Inc. and ReViral Ltd. valued at $20 million upfront payment, up to $135 million in potential milestones (effective 2022-12-16).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Pfizer Inc. and ReViral Ltd.
  - Value: $20 million upfront payment, up to $135 million in potential milestones
  - Effective: 2022-12-16
  source text: On December 16, 2022, LianBio Development HK Limited and LianBio Respiratory Limited, each a wholly-owned subsidiary of LianBio (the “Company,” and collectively with LianBio Development HK Limited and LianBio Respiratory Limited, “LianBio”), Pfizer Inc. (“Pfizer”) and ReViral Ltd. (“ReViral,” now a wholly-owned subsidiary of Pfizer) entered into a commercial agreement (the “Commercial Agreement”) with respect to sisunatovir (a fusion inhibitor product for treatment of respiratory syncytial virus (or RSV)) as the first Opted-in Product under the Strategic Collaboration Agreement dated November 17, 2020 by and between the Company and Pfizer (the “Collaboration Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/0001831283-22-000082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.